20 articles
New research reveals how chronic inflammation varies by person, paving the way for personalized interventions to combat age-related diseases.
New research reveals how low-grade inflammation creates a cycle of liver damage in older adults, pointing to promising therapeutic targets.
A major cross-population study finds that chronic inflammation linked to aging may reflect industrialized lifestyles, not biology alone.
BioAge's oral NLRP3 inhibitor BGE-102 cut hsCRP by ~85% in weeks, signaling a potential breakthrough in treating chronic inflammation at scale.
New therapies targeting inflammation pathways could reduce cardiovascular disease and slow kidney disease progression in CKD patients.
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
New research links chronic low-grade inflammation to faster epigenetic aging, measured across four validated biological clocks.
New research reveals how fat-derived molecules naturally shut down inflammation, offering hope for safer arthritis and heart disease treatments.
BioAge's oral drug BGE-102 dramatically reduced hsCRP and IL-6 in obese participants with elevated inflammation, with a strong safety profile.
A landmark 2025 review maps the molecular and cellular mechanisms driving immune aging, linking inflammaging to cancer, neurodegeneration, and infection.
New research maps the connection between cellular senescence, chronic inflammation, and cardiovascular disease progression.
Researchers identify how immune cell cleanup failures drive heart disease and develop targeted therapies to restore vascular health.
New research reveals kidneys actively fuel systemic inflammation during aging, offering targets for longevity interventions.
A peptide-loaded nanocomposite hydrogel disrupts the oxidation-inflammation-aging cycle driving osteoarthritis, protecting cartilage in rat models.
Researchers discover how glucocorticoids, metformin, and dimethyl fumarate work by targeting immune cell metabolism pathways.
BioAge's oral drug BGE-102 cut a key cardiovascular risk biomarker by up to 86% in obese patients, rivaling higher doses at just 60mg daily.
New review maps the glial cell pathways linking chronic neuroinflammation to Alzheimer's, Parkinson's, and ALS — and ranks drugs that may help.
New research reveals how immune aging creates systemic inflammation that accelerates kidney disease, autoimmune conditions, and other age-related illnesses.
Researchers identify specific inflammatory kidney cells that could be targeted with existing drugs to slow chronic kidney disease progression.
Research from sub-Saharan Africa shows urbanization dramatically alters inflammaging patterns, challenging universal aging models.
